Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Lymphoma 7Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Recurrence 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Primary Myelofibrosis 3Hereditary Sensory and Autonomic Neuropathies 2Advanced Malignancies 2Unresectable or Metastatic Solid Tumors 1Solid Tumors 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1B-Cell Malignancies 1

Interventions

Rituximab 30ibrutinib 26Bendamustine Hydrochloride 18Cyclophosphamide 17acalabrutinib 14fludarabine 13Lenalidomide 11zanubrutinib 10venetoclax 9Vincristine 7Bortezomib 7pirtobrutinib 5brexucabtagene autoleucel 5Prednisone 5Doxorubicin 5temsirolimus 4parsaclisib 4aflibercept 4Gemcitabine 4ublituximab 3orelabrutinib 3loncastuximab tesirine 3idelalisib 3ibritumomab tiuxetan 3Sensitivity and Specificity 3Antigens, CD19 3tositumomab I-131 2tazemetostat 2pembrolizumab 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Mantle-Cell × parsaclisib × Clear all
NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Incyte Corporation

Phase 1 Completed
50 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03235544 2025-03-18

(CITADEL-205)

Incyte Corporation

Phase 2 Completed
162 enrolled 18 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03314922 2023-08-14

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Incyte Corporation

Phase 1 Completed
17 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04849715 2022-04-29

CITADEL-310

Incyte Corporation

Phase 3 Withdrawn
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡